Table 2.

Treatment-Related Toxicity According to CTCAE v3.0 (N = 51)

AE	Grade 1 or 2		Grade 3 or 4
	No.	Frequency (%)	No.	Frequency (%)
Nonhematologic
Venous thromboembolism	0	0	10	20
Infection	1	2	6	12
Fatigue	49	96	5	10
Increased LFTs	35	69	5	10
Bleeding	24	47	4	8
Constipation	39	76	3	6
Nausea	27	53	3	6
Pain	11	22	3	6
Renal impairment	37	73	2	4
Neuropathy	17	33	1	2
Weight loss	14	27	1	2
Hypertension	2	4	1	2
Duodenal ulcer	1	2	1	2
Cardiac ischemia	0	0	1	2
Pneumonitis	0	0	1	2
Proteinuria	0	0	1	2
Increased amylase/lipase	1	2	1	2
Dyspnea	17	33	0	0
Diarrhea	16	31	0	0
Skin toxicity	15	29	0	0
Mucositis	12	24	0	0
Edema	11	22	0	0
Muscle weakness	7	14	0	0
GI obstruction	1	2	0	0
Fever	1	2	0	0
Hematologic
Febrile neutropenia	0	0	1	2
Neutropenia	32	63	16	31
Leukopenia	44	86	12	24
Thrombocytopenia	38	75	11	22
Anemia	50	98	10	20
Lymphopenia	0	0	8	16

Abbreviations: AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; LFT, liver function test.